Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

About this update from Organogenesis Holdings Inc.

CANTON, Mass. , July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, August 8th . Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here , or dial (800) 715-9871 and provide access code 6679912. The live webcast can also be accessed via the company’s website at investors.organogenesis.com . The webcast will be archived on the company website for approximately one year. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com . Investor Inquiries: ICR Westwicke Mike Piccinino , CFA [email protected] Press and Media Inquiries: Organogenesis [email protected] Source: Organogenesis Holdings Inc.

View stock analysis, news, and events for Organogenesis Holdings Inc.